Inactive

This is a Notice of Intent, not a request for proposal. The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other th... This is a Notice of Intent, not a request for proposal. The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other than full and open competition basis with Genesee Scientific, Morrisville, MD 27560 to procure a Elutriation Chamber for JE5.O Elutriation Rotor 1 Chamber/Unit; JES.O Elutriation Rotor Kit/Unit; and an AJ-20 Elutriation Upgrade Kit/Unit, which are accessories for the Elutriation centrifuge. The Molecular Pathology Section (MPS) focuses on (a) cancer genetics, mouse, and Drosophila embryogenesis, tumor suppressive genes, transgenic mice, transcriptional regulation and factors including Zn-finger proteins and nuclear receptors, and mechanics of DNA-protein and/or protein-protein recognition, and (b) studies of an evolutionarily conserved transcription factor called CTCF with multiple DNA sequence specificity, and a novel candidate tumor suppressor gene; studies also include but are not limited to (a) expression regulation of CTCF and by CTCF, (b) mutational analyses of CTCF in human cancers, (c) characterization of embryogenesis and tumorigenesis using recently developed CTCF transgenic mice strains, (d) targeted in vivo mutagenesis in a variety of CTCF-target. The MPS relies heavily on Elutriation Centrifuge in their mission to target diseases. The centrifuge is required for purification of human monocytes from PBMC to prepare dendritic cells required for personalized anti-breast cancer vaccine preparation. Those are Phase 1 Clinical trials that are going to be performed in collaboration with the Medical company Ilaya. This specific centrifuge is required for purification of human monocytes from PBMC to prepare dendritic cells for personalized anti-breast cancer vaccine preparation. The product results of this project will contribute to the medical society in the field of cancer treatment. Place of performance is Bethesda, MD. The statutory authority for this sole source requirement is 41 U.S.C. 253 (c) (1) as implemented by FAR 6.302-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide comparable services may submit a capability statement that will be considered by email (subject line to reference NOI-NIAID-2019722 to Rita Davis at rita.davis@nih.gov by 1:00 pm eastern standard time, May 7, 2020. All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.